End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
21,900 KRW | 0.00% | +2.10% | -4.37% |
03-14 | Seegene, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
01-24 | Seegene Inc. Announces Collaboration with Microsoft to Realize a World Free from All Diseases | CI |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Strengths
- The company's profit outlook over the next few years is a strong asset.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- With an expected P/E ratio at 66.36 and 23.47 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-4.37% | 733M | C+ | ||
-20.45% | 10.82B | A- | ||
+43.17% | 3.25B | D+ | ||
-35.86% | 2.11B | C | ||
-17.21% | 2.08B | - | B- | |
-29.81% | 1.48B | C+ | ||
+17.56% | 1.02B | B- | ||
-37.00% | 391M | C- | ||
-46.94% | 377M | C- | ||
+13.32% | 332M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- A096530 Stock
- Ratings Seegene, Inc.